Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTE NASDAQ:IRON NASDAQ:MESO NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$66.27+0.9%$64.46$43.70▼$86.53$2.09B-1.534,147 shs28,232 shsIRONDisc Medicine$59.94-0.7%$58.94$30.82▼$68.73$2.10B0.77308,980 shs318,138 shsMESOMesoblast$15.56+3.7%$14.30$6.00▼$22.00$1.92B2.26213,413 shs373,576 shsZVRAZevra Therapeutics$7.98-2.8%$10.52$6.19▼$13.16$460.87M1.561.63 million shs1.77 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+0.90%+4.35%-4.65%+6.65%+35.52%IRONDisc Medicine-0.66%-2.68%+2.30%+13.72%+20.99%MESOMesoblast+3.73%+20.81%+5.85%+27.96%+155.08%ZVRAZevra Therapeutics-2.80%-10.54%-31.79%-14.83%+10.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$66.27+0.9%$64.46$43.70▼$86.53$2.09B-1.534,147 shs28,232 shsIRONDisc Medicine$59.94-0.7%$58.94$30.82▼$68.73$2.10B0.77308,980 shs318,138 shsMESOMesoblast$15.56+3.7%$14.30$6.00▼$22.00$1.92B2.26213,413 shs373,576 shsZVRAZevra Therapeutics$7.98-2.8%$10.52$6.19▼$13.16$460.87M1.561.63 million shs1.77 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+0.90%+4.35%-4.65%+6.65%+35.52%IRONDisc Medicine-0.66%-2.68%+2.30%+13.72%+20.99%MESOMesoblast+3.73%+20.81%+5.85%+27.96%+155.08%ZVRAZevra Therapeutics-2.80%-10.54%-31.79%-14.83%+10.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 3.00Buy$96.6745.87% UpsideIRONDisc Medicine 3.09Buy$98.3064.00% UpsideMESOMesoblast 3.20Buy$18.0015.68% UpsideZVRAZevra Therapeutics 2.89Moderate Buy$23.71197.17% UpsideCurrent Analyst Ratings BreakdownLatest ZVRA, IRON, BLTE, and MESO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$85.00 ➝ $90.008/18/2025ZVRAZevra TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/13/2025ZVRAZevra TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$19.00 ➝ $18.008/5/2025MESOMesoblastCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/21/2025IRONDisc MedicineWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$90.007/21/2025IRONDisc MedicineTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$86.007/18/2025MESOMesoblastJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold7/10/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $29.007/3/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.007/3/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$85.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$4.72 per shareN/AIRONDisc MedicineN/AN/AN/AN/A$14.85 per shareN/AMESOMesoblast$17.20M115.80N/AN/A$4.67 per share3.33ZVRAZevra Therapeutics$23.61M18.97N/AN/A$0.74 per share10.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$36.14M-$1.55N/AN/AN/AN/A-34.90%-33.56%11/11/2025 (Estimated)IRONDisc Medicine-$109.36M-$4.47N/AN/AN/AN/A-26.60%-24.58%11/11/2025 (Estimated)MESOMesoblast-$102.14MN/A0.00N/AN/AN/AN/AN/AN/AZVRAZevra Therapeutics-$105.51M-$0.21N/A39.90N/A4.33%-112.40%-37.67%11/11/2025 (Estimated)Latest ZVRA, IRON, BLTE, and MESO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025BLTEBelite Bio-$0.47-$0.50-$0.03-$0.50N/AN/A8/7/2025Q2 2025IRONDisc Medicine-$1.17-$1.58-$0.41-$1.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A23.1523.15IRONDisc Medicine0.0532.1132.11MESOMesoblast0.111.991.77ZVRAZevra Therapeutics0.527.857.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%IRONDisc Medicine83.70%MESOMesoblast1.43%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%IRONDisc Medicine3.64%MESOMesoblast18.80%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableIRONDisc Medicine3034.77 million33.50 millionNot OptionableMESOMesoblast80128.00 million103.93 millionOptionableZVRAZevra Therapeutics2056.13 million54.79 millionOptionableZVRA, IRON, BLTE, and MESO HeadlinesRecent News About These CompaniesZevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Increase in Short InterestSeptember 9 at 2:53 AM | marketbeat.comZevra Therapeutics, Inc. $ZVRA Stock Holdings Trimmed by Adage Capital Partners GP L.L.C.September 7, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $23.71 Consensus Target Price from AnalystsSeptember 6, 2025 | americanbankingnews.comZevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)September 4, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 4, 2025 | marketbeat.comZevra Therapeutics, Inc. $ZVRA Shares Sold by Nantahala Capital Management LLCSeptember 3, 2025 | marketbeat.comRetirement Planning Co of New England Inc. Has $4.12 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRASeptember 2, 2025 | marketbeat.comWellington Management Group LLP Purchases New Shares in Zevra Therapeutics, Inc. $ZVRASeptember 2, 2025 | marketbeat.comVelan Capital Investment Management LP Increases Stake in Zevra Therapeutics, Inc. $ZVRAAugust 31, 2025 | marketbeat.comZevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)August 28, 2025 | globenewswire.comZevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLCAugust 26, 2025 | marketbeat.comZevra Therapeutics to Participate at Upcoming Investor Conferences in SeptemberAugust 26, 2025 | globenewswire.comZacks Research Downgrades Zevra Therapeutics (NASDAQ:ZVRA) to HoldAugust 22, 2025 | marketbeat.comZevra Therapeutics rumor highlighted in Betaville blogAugust 21, 2025 | msn.comZevra Therapeutics gains amid takeover speculationAugust 21, 2025 | msn.comZevra Therapeutics (NASDAQ:ZVRA) Director John Bode Buys 5,000 SharesAugust 21, 2025 | insidertrades.comZevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 4.4% - Should You Buy?August 17, 2025 | marketbeat.comCantor Fitzgerald Brokers Lower Earnings Estimates for ZVRAAugust 17, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZVRA Q3 EarningsAugust 17, 2025 | marketbeat.comQ3 EPS Forecast for Zevra Therapeutics Increased by AnalystAugust 17, 2025 | marketbeat.comHC Wainwright Has Bearish Estimate for ZVRA FY2027 EarningsAugust 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025New Age Warfare: Anduril Is the Hype, AeroVironment Is the BuyBy Jeffrey Neal Johnson | August 28, 2025Take the Money and Run: Strategy Stock Looks Tapped OutBy Gabriel Osorio-Mazilli | September 9, 2025ZVRA, IRON, BLTE, and MESO Company DescriptionsBelite Bio NASDAQ:BLTE$66.27 +0.59 (+0.90%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$64.15 -2.12 (-3.20%) As of 09/10/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Disc Medicine NASDAQ:IRON$59.94 -0.40 (-0.66%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$59.98 +0.04 (+0.07%) As of 09/10/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Mesoblast NASDAQ:MESO$15.56 +0.56 (+3.73%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$15.61 +0.05 (+0.34%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Zevra Therapeutics NASDAQ:ZVRA$7.98 -0.23 (-2.80%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$8.04 +0.06 (+0.81%) As of 09/10/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
